Published in:
Open Access
01-12-2010 | Poster presentation
Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
Authors:
JJD Furtado, JV Madruga, EL Bicudo, M Eira, MIB Lopes, EM Netto, MS de Oliveira, OHM Leite, AA Machado, U Tupinambas, JL de Andrade Neto, MPJ Lima, DB Wajsbrot, LM Cassoli
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
MVC is the first-in-class CCR5 antagonist approved for use in treatment of CCR5-tropic (R5) HIV-1 infection; however, there is limited experience with MVC in regimens containing newer PIs and other new agents. This open-label 96-week multi-center study evaluates MVC in a variety of regimens to obtain additional safety and efficacy data in TE patients with limited options due to intolerance or resistance in Brazil. …